NCT05145647Active, not recruiting
To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery
To Observe the Local Tumor Recurrence Rate of Adding Intraluminal Brachytherapy With Balloon Applicator After Standard Definitive Concurrent Chemoradiotherapy (CCRT) on Local-regional Thoracic Esophageal Cancer Patients Who Refused Surgery
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
Clinical experience of adding intraluminal brachytherapy with traditional applicator after definitive concurrent chemoradiotherapy (CCRT) for local-regional thoracic esophageal cancer is limited due to high complication risk and non-superiority in survival. The innovative applicator can maximize the therapeutic efficacy by reducing dose inhomogeneity in the esophageal wall, which will translate into less over-dosing and less risk of the side effects of fistula or stenosis. The primary goal of this study by using new applicator is to observe the change in local tumor control rate, while secondary goals are treatment related toxicity, progression-free survival, and overall survival.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 3 Sept 2021
- Start date
- 30 Mar 2022
- Primary completion date
- 18 Oct 2026
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05145647
What you commit to
- Study type: Interventional
- Planned participants: 18
- From 30 Mar 2022 to the primary completion date, 18 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- T4b tumor status (tracheal / bronchial mucosa, aortic involvement, or fistula formation).
Other
- Stenosis of esophageal lumen that cannot be bypassed by the applicator.
- The primary tumor length exceeds 20cm.
- The patient is participating in other clinical trials.
Who the study is looking for
- Age of 20-85 years, with ECOG performance 0-2
- Thoracic esophageal cancer with clinical stage I-III and biopsy proof; patient with cervical esophageal cancer or stage IV thoracic esophageal cancer could be recruited in this trial according to Investigator's assessment.
- Complete first course CCRT with minimum doses of 40 Gy to tumor and nodal area via external beam radiotherapy (EBRT).
- Patient whose tumor is resectable but declined to receive surgery after first course CCRT.
Age in the registry: 20 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Linkou Chang-Gung Memorial Hospital Coordinator of this site? Confirm its status | Taoyuan City | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.